Metabolic syndrome and target organ damage: Role of blood pressure

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 5, 2008, Pages 731-743

  Cuspidi, Cesare ^a   Sala, Carla ^a   Zanchetti, Alberto ^a  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Carotid atherosclerosis; Hypertension; Left ventricular hypertrophy; Metabolic syndrome; Microalbuminuria

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; LACIDIPINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEBIVOLOL; RENIN INHIBITOR; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

ARTERY CALCIFICATION; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DRUG MECHANISM; DYSLIPIDEMIA; ELECTROCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; FATALITY; GENETIC TRAIT; GLUCOSE BLOOD LEVEL; GOUT; HEART HYPERTROPHY; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INTERNAL CAROTID ARTERY OCCLUSION; KIDNEY DISEASE; LIFESTYLE MODIFICATION; LOW CALORY DIET; LOW DRUG DOSE; METABOLIC DISORDER; METABOLIC SYNDROME X; MICROALBUMINURIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PATIENT MONITORING; PHENOTYPE; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION; AGED; COMORBIDITY; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE FUNCTION; HOSPITALIZATION; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL;

AGED; AGED, 80 AND OVER; COMORBIDITY; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; KIDNEY DISEASES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 47149112768     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.5.731     Document Type: Review

References (81)

1. Zavaroni I, Bonora E, Pagliara M et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N. Engl. J. Med. 320(11), 702-706 (1989).
2. Dandona P, Aljada A, Chaudhurri A et al. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 109(11), 1448-1454 (2005).
3. Rantala AO, Kauma H, Lilja M, Savolainen MJ, Reunanen A, Kesaniemi YA. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J. Intern. Med. 245(2), 163-174 (1999).
4. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stem MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 41(6), 715-722 (1992).
5. Hu G, Qiao Q, Tuomiletho J et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in non-diabetic European men and women. Arch. Intern. Med. 164 (10), 1066-1076 (2004).
6. Trevisan M, Liu J, Bahas FB, Menotti A. Syndrome X and mortality: a population based study. Am. J. Epidemiol. 148(10), 958-966 (1998).
7. Malik S, Wong ND, Franklin SS et al. Impact of the metabolic syndrome on mortality from coronary heart disease, and all cause in United States adults. Circulation 110(10), 1245-1250 (2004).
8. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288(21), 2709-2716 (2002).
9. Reaven GM. Role of insulin resistance in human disease. Diabetes 37, 1595-1607 (1988).
10. Reaven GM. Syndrome X: six year later. J. Intern. Med. 236(Suppl. 736), 13-22 (1994).
11. Kesaniemi YA, Lilja M, Kervinen K, Rantala A. Multiple metabolic syndrome: aspects of generic epidemiology and molecular genetics. Am. Med. 24(6), 461-464 (1992).
12. Schmidt MI, Duncan BB, Watson RL, Shatter RL, Brancati FL, Heiss G. A metabolic syndrome in White and African Americans. The Atherosclerosis Risk in Communities baseline study. Diabetes Care 19(5), 414-418 (1996).
13. Kaplan NM. The deadly quartet. Upper body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch. Intern. Med. 149(7), 1514-1520 (1989).
14. Redon J, Cifkova R. The metabolic syndrome in hypertension: diagnostic and therapeutic implications. Curr. Hypertens. Rep. 9(4), 305-313(2007).
15. Verdecchia P, Schillaci G, Borgioni C et al. Prognostic value of left ventricular mass and geometry in systemic hypertension with left ventricular hypertrophy. Am. J. Cardiol. 78(2), 197-202 (1996).
16. Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J. Am. Coll. Cardiol. 25(4), 197-202 (1995).
17. Toubol PJ, Labreuche J, Vicaut E, Amarenco P; GENIC Investigators. Carotid intima-media thickness, plaques, and Framingham risk score as independent determinants of stroke risk. Stroke 36(8), 1741-1745 (2005).
18. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N. Engl. J. Med. 340(1), 14-22 (1999).
19. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25(9), 1105-1187 (2007).
20. Avogaro P, Crepaldi G, Enzi G, Tiengo A. Associazione di iperlipidemia, diabete mellito e obesità di medio grado. Acta Diabet. Lat. 4, 36-41 (1967).
21. Haller H. Epidemiologie und assoziierte risikofaktofen der hyperlipoproteinamie (Epidemiology and associated risk factors of hyperlipoproteinemia). Z. Gesamte Inn. Med. 32, 124-128 (1977).
22. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15(7), 539-553 (1998).
23. Balkan B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet. Med. 16(5), 442-443 (1999).
24. Executive Summary: The third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285(19), 2486-2497 (2001).
25. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17), 2375-2352 (2005).
26. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. JAMA 287(3), 356-359 (2002).
27. Mancia G, Bombelli M, Corrao G et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage and prognosis. Hypertension 49(1), 40-47 (2007).
28. Maggi S, Noale M, Zambon A, Limongi F, Romanato G, Crepaldi G. Validity of the ATP criteria for the metabolic syndrome in an elderly Italian Caucasian population. The Italian Longitudinal Study on Aging. Atherosclerosis 197(2), 877-882 (2008).
29. Myoung-Hee K, Mi-Kyung K, Bo-Youl C, Young-Jean S. Prevalence of the metabolic syndrome and its association with cardiovascular diseases in Korea. J. Korean Med. Sci. 19, 195-201 (2004).
30. Zimmer P, Alberti KG, Kaufman F et al. The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr. Diabetes 8(5), 299-306 (2007).
31. Duncan GE, Sierra ML, Zhou XH. Prevalence and trends of a metabolic syndrome phenotype among US adolescents, 1999-2000. Diabetes Care 27(10), 2438-2443 (2004).
32. Weiss R, Dziura J, Burger TS et al. Obesity and the metabolic syndrome in children and adolescents. N. Engl. J. Med. 350(23), 2362-2374 (2004).
33. Llyod-Jones DM, Liu K, Colangelo LA et al. Consistently stable or decreased body mass index in young adulthood and longitudinal changes in metabolic syndrome components: the Coronary Artery Risk Development in Young Adults Study. Circulation 115(8), 1004-1011 (2007).
34. Cuspidi C, Meani S, Fusi V et al. Metabolic syndrome and target organ damage in untreated essential hypertensives. J. Hypertens. 22(10), 1991-1998 (2004).
35. Cuspidi C, Meani S, Valerio C et al. Age and target organ damage in essential hypertension: role of the metabolic syndrome. Am. J. Hypertens. 20(3), 296-303 (2007).
36. Navarro J, Redon J, Cea-Calvo L et al. Metabolic syndrome, organ damage and cardiovascular disease in treated hypertensive patients The ERIC-HTA study. Blood Press. 16(1), 20-27 (2007).
37. Bog-Hansen E, Lindblad U, Gullberg B, Melander A, Rastam L. Metabolic disorders associated with uncontrolled hypertension. Diabetes Obes. Metab. 5(6), 379-87 (2003).
38. Ishikawa S, Shibano Y, Asai Y, Kario K, Kayaba K, Kajh E. Blood pressure categories and cardiovascular risk factors in Japan: the Jichi Medical School (JMS) cohort study. Hypertens. Res. 30(7), 643-649 (2007).
39. Ferrara LA, Cardoni O, Mancini M, Zanchetti A. Metabolic syndrome and left ventricular hypertrophy in a general population. Results from the Gubbio Study. J. Hum. Hypertens. 21(10), 795-801 (2007).
40. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J. Clin. Endocrinol. Metab. 86, 713-718 (2001).
41. Chobanian AV, Bakris GR, Black HF et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 289(19), 2560-2572 (2003).
42. Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new Joint National Committee guidelines. Arch. Intern. Med. 164(19), 2126-2134 (2004).
43. Greenland KJ, Croft JB, Mensah GA. Prevalence of heart disease and stroke risk factors in persons with prehypertension and hypertension in the United States, 1999-2000. Arch. Intern. Med. 164(19), 2113-2118 (2004).
44. Cordero A. Laclaustra M, Leon M et al. Prehypertension is associated with insulin resistance state and not with an initial renal function impairment. A Metabolic Syndrome in Active Subjects in Spain (MESYAS) Registry Substudy. Am. J. Hypertens. 19 (2), 189-196 (2006).
45. Choi KM, Park HS, Han JH et al. Prevalence of prehypertension and hypertension in a Korean population: Korean National Health and Nutrition Survey 2001. J. Hypertens. 24(8), 1515-1521 (2006).
46. 2003 WHO/International Society of Hypertension (ISH) statement of hypertension. World Health Organization, International Society of Hypertension Writing Group. J. Hyperiens. 21(11), 1983-1992 (2003).
47. Verdecchia P, Angeli F. Borgioni C et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am. J. Hypertens. 16(11), 895-899 (2003).
48. Olsen MH, Wachtell K, Ibsen H et al. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J. Hypertens. 24(4), 775-781 (2006).
49. Leonetti G, Cuspidi C. Heart and vascular changes in hypertension. J. Hypertens. 13(2, Suppl. 2), S29-S34 (1995).
50. Sega R, Trocino G, Lanzarotti A et al. Alterations of cardiac structure in patients with isolated, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA]) Study. Circulation 104(12), 1385-1392 (2001).
51. Schmieder R. The role of non-haemodynamic factors of the genesis of LVH. Nephron Dial. Transplant. 20, 2610-2612 (2005).
52. Chinali M, Devereux RB, Howard BV et al. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (The Strong Heart Study). Am. J. Cardiol. 93(1), 40-44 (2004).
53. Burchfiel CE, Skelton TN, Andrew ME et al. Metabolic syndrome and echocardiographic left ventricular mass in blacks. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 112(6), 819-827 (2005).
54. Eguchi K, Schwartz JE, Roman MJ et al. Metabolic syndrome less strongly associated with target organ damage than syndrome components in a healthy, working population. J. Clin. Hypertens. 9(5), 337-344 (2007).
55. Leoncini G, Ratto E, Viazzi F et al. Metabolic syndrome is associated with early signs of organ damage in non-diabetic, hypertensive patients. J. Intern. Med. 257(5), 454-460 (2005).
56. Mulè G, Nardi F, Cottone S et al. Influence of metabolic syndrome on hypertension-related target organ damage. J. Intern. Med. 257(6), 503-513 (2005).
57. Schillaci G, Pirro M, Pucci G et al. Different impact of the metabolic syndrome on left ventricular structure and function in hypertensive men and women. Hypertension 47(5), 881-886 (2006).
58. de Simone G. State of the art in the metabolic syndrome. Nutr. Metab. Cardiovasc. Dis. 15, 239-241 (2005).
59. de Simone G, Devereux RB, Kizewr JR et al. Body composition and fat distribution influence systemic hemodynamics in the absence of obesity: the HyperGEN Study. Am. J. Clin. Nutr. 81(4), 757-761 (2005).
60. Rutter MK, Parise H, Benjamin EJ et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 107(3), 448-454 (2003).
61. Vaudo G, Schillaci G, Evangelista F, Pasqualini L, Verdecchia P, Mannarino E. Arterial wall thickening at different sites and its association with left ventricular hypertrophy in newly diagnosed essential hypertension. Am. J. Hypertens. 13(4), 324-331 (2000).
62. Bots ML, Van Swieten JC, Breteler MM et al. Cerebral white matter lesions an atherosclerosis in the Rotterdam Study. Lancet 341(4), 1231-1237 (1993).
63. Davis PH, Dawson JD, Mahoney IT, Lauer RM. Increased carotid intimal-medial thickness and coronary calcification are related in young and middle-aged adults. The Muscatine study. Circulation 100(8), 838-842 (1999).
64. Scuteri A, Najjar S, Muller DC et al. Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J. Am. Coll. Cardiol. 43(8), 1388-1395 (2004).
65. Tzou WS, Douglas PS, Srinivasan SR et al Increased subclinical atherosclerosis in young adults with metabolic syndrome. The Bogalusa Heart Study. J. Am. Coll. Cardiol. 46(3), 457-463 (2005).
66. Iglseder B, Cip P, Malaimare L, Ladurner G, Paulweber B. The metabolic syndrome is a stronger risk factor for early atherosclerosis in women than in men. Stroke 36(6), 1212-1217 (2005).
67. Kawamoto R, Tomita H, Inoue A, Ohtuka N, Kamitami A. Metabolic syndrome may be risk factor for early atherosclerosis in women but not in men. J. Atheroscler. Thromb. 14(1), 36-43 (2007).
68. Teramura M, Emoto M, Araki T et al. Clinical impact of metabolic syndrome by modified NCEP-ATP III criteria on carotid atherosclerosis in Japanese adults. J. Atheroscler. Thromb. 14(4), 172-178 (2007).
69. Bertoni AG, Wong ND, Shea S et al. Insulin resistance, metabolic syndrome and subdinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 30(11), 2951-2956 (2007).
70. Zanchetti A, Bond ML, Hennig M et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine on Atherosclerosis (ELSA a randomized, double blind, longterm trial. Circulation 106 (19), 2422-2427 (2002).
71. Zanchetti A, Henning M, Baurecht H et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima media thickness. J. hypertens. 25(12), 2463-2470 (2007).
72. Kim J, Montagnani M, Koh KK, Quon MJ. Reciprocal relationship between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113, 1888-1904 (2006).
73. Ruilope LM, Salvetti A, Jamerson K et al. Renal function and intensive lowering of blood pressure in hypertensive paticipants of the Hypertension Optimal Treatment (HOT) study. J. Am. Soc. Nephrol. 12(2), 218-225 (2001).
74. De Leeuw PW, Ruilope LM, Palmer CM et al. Clinical significance of renal function in hypertensive patients at high risk. results from the INSIGHT trial. Arch. Intern. Med. 164(22), 2459-2464 (2004).
75. Liese AD, Hense HW, Doring A, Stieber J, Keil U. Microalbuminuria, central adiposity and hypertension in the non-diabetic urban population of the Monica Ausburg survey 1994-1995. J. Hum Hypertens. 150(11), 799-804 (2001).
76. Hoehner CM, Greenlund KJ, Rith-Najarian S, Casper ML, McClellan WM. Association of the insulin resistance syndrome and microalbuminuria among native Americans. The Inter-tribal Heart Project. J. Am. Soc. Nephrol. 13(6), 1626-1634 (2002).
77. Palaniappan L, Carnethon M, Fortmann S. Association between microalbuminuria and the metabolic syndrome: NANHES III. Am. J. Hypertens. 16(11), 952-958 (2003).
78. Grandi AM, Santillo R, Zanzi P. et al. Microalbuminuria in never-treated hypertensives: lack of relationship to hyperinsulinemia and genetic predisposition to hypertension. Am. J. Hypertens. 13(4), 353-358 (2000).
79. Pedrinelli R, Dell'Omo G, Penno G et al. Microalbuminuria, pararameter independent of metabolic influences in hypertensive men. J. Hypertens. 21(6), 1163-1169 (2003).
80. Lindholm LH, Persson M, Alaupovic P et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J. Hypertens. 21(8), 1459-1462 (2003).
81. Celik T, Iyisoy A, Kursaklioglu H et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J. Hypertens. 24(3), 591-596 (2006).